Lithium Ion

Lithium Ion

SCHEMBL3678754

CC(C)c1csc(C(=O)[O-])n1.[Li+]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
GRM1 Q13255 1/20 0.37
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
CSNK2A3 Q8NEV1 1/20 0.33
TRPA1 O75762 1/20 0.33
NTRK1 P04629 1/20 0.33
PTGER1 P34995 1/20 0.33
UCHL1 P09936 1/20 0.33
CCR4 P51679 1/20 0.33
AURKA O14965 1/20 0.32
RPS6KB1 P23443 1/20 0.32
GAA P10253 1/20 0.31
PLAT P00750 1/20 0.30
GCK P35557 2/20 0.30
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL22518563 0.96 CYP1A2 (0.37) CYP1A2CYP2D6CYP2C9GRM1CSNK2A2
SCHEMBL313040 0.81 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C9GRM1CSNK2A2
SCHEMBL2624132 0.79 AURKA (0.39) CYP1A2CYP2D6CYP2C9GRM1CSNK2A2
SCHEMBL20780324 0.73 CCR4 (0.34) CYP1A2CYP2D6CYP2C9GRM1TRPA1
Lithium Ion SCHEMBL20746311 0.71 GRM5 (0.44) PTGER1
Lithium Ion SCHEMBL31223897 0.71 CSNK2A1 (0.35) CSNK2A1PTGER1
Lithium Ion SCHEMBL31223893 0.71 CSNK2A1 (0.35) CSNK2A1PTGER1
Lithium Ion SCHEMBL3799858 0.66 MAPT (0.47) GAAPLATGCK
SCHEMBL12190585 0.66 L3MBTL1 (0.57) CYP1A2CYP2D6CYP2C9GRM1CSNK2A2
SCHEMBL20780330 0.64 CCR4 (0.36) CYP1A2CYP2D6CYP2C9GRM1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393493-A1 COMPOUNDS GlaxoSmithKline LLC (US) 2011-12-14 EP disclosed
US-20100196321-A1 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-05 US disclosed
WO-2010088394-A1 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196321-A1 COMPOUNDS HAVCR2, ACE, ACE2 CYP1A2 51/4885CYP2D6 47/4885CYP2C9 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.